Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Videos|October 2, 2026
PharmTech AI Pulse Check: Episode 2 - Shadow AI, Trade Secrets, the API Race
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
Advertisement
Advertisement
In the second episode of PharmTech's new biweekly video series, “PharmTech AI Pulse Check,” host Chris Cole, associate editorial director, PharmTech, sits down with three expert co-hosts—Richard Jaenisch, Open Biopharma Research and Training Institute, Florin Muraru, independent regulatory affairs advisor, and Gourav Pandey, R&D quality lead, Takeda—to unpack three fast-moving flashpoints in pharma AI: data governance, the shift toward API-gated scientific literature, and the limits of AI-content detection.
Related to this article
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
Jaenisch, Muraru, and Pandey debate whether AI "slop" is infiltrating pharma SOPs and deviation reports and who should catch it first.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement